Future scenarios for the prevention and delay of Alzheimer disease onset in high-risk groups: An ethical perspective

American Journal of Preventive Medicine

Volumn 16, Issue 2, 1999, Pages 105-110

  Post, Stephen G ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age of onset; Alzheimer disease; Ethics; Prevention

Indexed keywords

DONEPEZIL;

ACCURACY; AGING; ALZHEIMER DISEASE; DEMENTIA; ETHICS; FUTUROLOGY; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; ONSET AGE; PRIVACY; REVIEW;

EID: 0033061097     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-3797(98)00139-1     Document Type: Article

References (33)

1. Evans D.A., Funkenstein H.H., Albert M.S., et al. Prevalence of Alzheimer's disease in a community population of older persons Higher than previously reported . JAMA. 262:1989;2551-2556.
2. Aevarsson O., Skoog I. A population-based study on the incidence of dementia disorders between 85 and 88 years of age. J Am Geriatr Soc. 44:1996;1455-1460.
3. Evans D.A., Scherr P.A., Cook N.R., et al. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q. 68:(2):1990;267-289.
4. Gladwell M. The Alzheimer's strain How to accomodate too many patients . The New Yorker. 27:October 20, 1997;125-127.
5. Ineichen B. Senile dementia in Japan Prevalence and response . Soc Sci Med. 42:(2):1996;169-172.
6. Rice D.P., Fox P.J., Max W., et al. The economic burden of Alzheimer's disease care. Health Aff. 12:(2):1993;164-176.
7. Alzheimer's Association. 1999-2001 strategic plan. Chicago: Alzheimer's Association, 2 November 1997.
8. A world without Alzheimer's disease A dream within reach . 1997;Alzheimer's Association, Chicago.
9. Alzheimer's Association. Program Announcement: 1998 Research Grants Program of the Alzheimer's Association. Chicago: Alzheimer's Association, 1998.
10. U.S. Department of Health and Human Services, Recognition and Initial Assessment of Alzheimer's Disease and Related Dementias. Rockville, MD: Agency for Health Care Policy and Research, No. 97-0702, 1996.
11. Post S.G. Physician-assisted suicide in Alzheimer disease. J Am Geriatr Soc. 45:1997;647-651.
12. Pokorski R.J. Insurance underwriting in the genetic era. Am J Hum Genet. 60:1997;205-216.
13. Post S.G., Whitehouse P.J. Binstock RH, et al. The clinical introduction of genetic testing for Alzheimer disease: an ethical perspective. JAMA. 277:1997;832-836.
14. Butler R. ApoE New risk factor for Alzheimer's . Geriatrics. 49:1994;10-11.
15. Post S.G., Whitehouse P.J. Genetics, ethics, and Alzheimer disease. 1998;The Johns Hopkins University Press, Baltimore, MD.
16. Rogers S.L., Farlow M.R., Doody R.S., et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 50:1998;136-145.
17. Rogers S.L., Friedhoff L.T. The efficacy and safety of Donepezil in patients with Alzheimer's disease results of a US multicentre, randomized, double-blind, placebo-controlled trial . Dementia. 7:1996;293-303.
18. Mohr E., Feldman H., Gauthier S. Canadian guidelines for the development of antidementia therapies a conceptual summary . Can J Neurol Sci. 22:1995;62-71.
19. Kelly C.A., Harvey R.J., Cayton H. Drug treatments for Alzheimer's disease raise clinical and ethical problems. Br Med J. 314:1997;693-694.
20. Whitehouse P.J., Juengst E., Mehlman M., et al. Enhancing cognition in the intellectually intact. Hastings Cent Rep. 27:(3):1997;14-22.
21. Tang M.X., Jacobs D., Stern Y., et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 348:(9025):1996;429-432.
22. Jacobs D.M., Tang M.X., Stern Y., et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology. 50:1996;1-6.
23. Resnick S.M., Metter E.J., Zonderman A.B. Estrogen replacement therapy and longitudinal decline in visual memory A possible protective effect? Neurology. 49:1997;1491-1497.
24. Kawas C., Resnick S., Morrison M.S., et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease The Baltimore longitudinal study of aging . Neurology. 48:1997;1517-1521.
25. Kuller L.H. Hormone replacement therapy and its potential relationship to dementia. J Am Geriatr Soc. 44:1996;878-880.
26. Schweain SL. Ginko. Review of Natural Products March 1998:5.
27. Le Bars P.L., Katz M.M., Berman N., et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginko biloba for dementia. JAMA. 278:1997;1327-1332.
28. Sano M., Ernesto C., Thomas R.G., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 336:1997;1216-1222.
29. Post S.G. Slowing the progression of dementia Ethical issues . Alzheimer Dis Assoc Disord. 11:(5):1997;34-36.
30. Picot S.J., Debanne S.M., Namazi K.H., et al. Religiosity and perceived rewards of black and white caregivers. Gerontologist. 37:1997;89-101.
31. Winblad B., Hill S., Beerman B., et al. Issues in the economic evaluation of treatment for dementia. Alzheimer Dis Assoc Disord. 11:(Suppl. 3):1997;39-44.
32. Post S.G., Whitehouse P.J. Emerging anti-dementia drugs A preliminary ethical view . J Am Geriatr Soc. 46:1998;784-787.
33. Post S.G. The moral challenge of Alzheimer disease. 1995;The Johns Hopkins University Press, Baltimore, MD.